Blood-test for cancer detection

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

HCCBloodTest – A blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma (HCC)

As the second-leading cause of global cancer death, hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, affecting more than 800,000 people annually. Major risk factors for HCC include cirrhosis, infection with hepatitis B (HBV) or C virus (HCV), alcoholic liver disease, and non-alcoholic fatty liver disease. Worldwide, approximately 80-90% of patients with HCC occur in the setting of underlying cirrhosis. Coupled with a 2-4% annual incidence for HCC, cirrhotic patients are classified as a high-risk group for surveillance efforts aimed at early detection when potentially curative treatments can be offered. Current surveillance strategies support screening for cirrhotic patients using abdominal ultrasound every 6 months, irrespective of etiology. While alpha-fetoprotein (AFP) has also been widely used as a diagnostic marker for HCC, it is insufficiently sensitive or specific for use alone in a screening or surveillance setting and is suboptimal for routine clinical practice. Therefore, better screening and diagnostic biomarker assays are needed to improve the early detection of HCC.

Shown to have a high diagnostic accuracy for the detection of HCC in cirrhotic patients, the HCCBloodTest offers an option to improve risk prediction and patient management.

Learn More.

Important document:

  • Instructions for Use PDF

 

Epi BiSKit – Plasma Kit (M7-01-001)
HCCBloodTest Sensitive PCR Kit (M8-001-002)
HCCBloodTest Control Kit (M8-001-003)

References

  • Villanueva A. (2015) DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 61(6):1945-1956.
  • Oussalah A. (2018) Plasma mSEPT9: A novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. EBioMedicine. https://doi.org/10.1016/j.ebiom.2018.03.029
  • Global Burden of Disease Liver Cancer Collaboration. (2017) The burden of primary liver cancer and underlying etiologies. From 1990 to 2015 at the global, regional and national level. Results for the Global Burden of Disease Study 2015. JAMA Oncol, 3(12):1683-1691.
  • Ghouri Y et al. (2017) Review of hepatocellular carcinoma: epidemiology, etiology and carcinogenesis. J Carcinogenesis, 16:1.
  • Tang A et al. (2018) Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol, 43:13-25.
  • Marrero J et al. (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatol, (68)2: 723-750.
  • Massoud O. (2018) Nonalcohlic fatty liver disease/nonalcoholic steatohepatitis and hepatocellular carcinoma. Clinics in Liver Disease, https://doi.org/10.1016/j.cld.2017.08.014
  • D’Avola D. (2016) Natural history of non-alcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: magnitude of the problem from a hepatology clinic perspective. Clinical Liver Disease, 8(4): 100-104.
  • Tzartzeva K. (2018) Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patient with cirrhosis: a meta-analysis. Gastroenterology, 154(6):1706-1716.